FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2552830230> ?p ?o ?g. }

• W2552830230 endingPage "330" @default.
• W2552830230 startingPage "330" @default.
• W2552830230 abstract "Abstract Survival expectations for acute myeloid leukemia (AML) patients remain poor, highlighting the need for further treatment options. The majority of AML blasts express CD123, the alpha subunit of the IL-3 receptor, which regulates the proliferation, survival and differentiation of hematopoietic cells. CD123 is also robustly expressed on leukemic stem cells and is a marker for minimal residual disease (MRD, Roug et al. 2012). Poor prognosis has previously been associated with elevated expression of CD123 on leukemic stem cells and blasts (Vergez et al. 2011, Testa et al. 2002). These findings identify CD123 as a rational therapeutic target in AML. Here we report the preclinical development of a novel CD123-directed immunoconjugate SGN-CD123A, consisting of a humanized anti-CD123 antibody conjugated to a highly potent DNA binding pyrrolobenzodiazepine (PBD) dimer drug via a protease-cleavable dipeptide linker. An engineered cysteine on each heavy chain attaching the PBD dimer to the antibody allows uniform drug loading of approximately two PBD dimers per antibody. Fluorescence microscopy studies show that SGN-CD123A is rapidly internalized and traffics to lysosomes within hours of binding to CD123-positive AML cells. Uptake of the antibody-drug-conjugate (ADC) induced DNA damage as measured by dose-and time-dependent increases in the phosphorylation of histone 2AX (γH2AX) and cell death associated with G2-M cell cycle arrest, caspase-3 activity, formation of cleaved poly ADP-ribose polymerase, and DNA fragmentation in target cells. The anti-leukemic activity of SGN-CD123A was assessed in cytotoxicity assays in 12 AML cell lines and 23 primary AML patient samples with variable cytogenetic abnormalities (favorable, intermediate and adverse) and multi-drug resistance (MDR) status. SGN-CD123A was highly active in 11 of 12 AML cell lines tested (mean IC50, 6 ng/ml; range of 0.02 to 38 ng/ml), including 4 of 5 MDR-positive cell lines, whereas it was inactive in CD123-negative HEL92.1.7 AML cells. SGN-CD123A was also active against 20 of 23 primary samples isolated from AML patients (mean IC50 of responsive samples, 0.8 ng/mL; range of 0.06 to 2.5 ng/ml). In both AML panels, molecular abnormalities, including the presence of a p53 mutation, FLT3-ITD, as well as MDR positivity, did not affect the in vitro cytotoxic activity of SGN-CD123A. In vivo antitumor activity was evaluated in AML xenograft models established with CD123-positive, MDR-negative Molm-13, HNT-34, and THP-1 cell lines and the MDR-positive KG-1 cell line. In all of the in vivo models, a single dose of SGN-CD123A delivered significant antitumor activity. SGN-CD123A dosed once at 10 mcg/kg yielded complete cures and significant survival advantage in the Molm-13 disseminated model of AML (p < 0.0001 compared to untreated or control ADC groups). Durable complete regressions were observed with a single dose of 25 or 75 mcg/kg in the MDR-negative HNT-34 subcutaneous model (p =0.0019 to control ADC group). In the THP-1 model, a single 100 mcg/kg dose of SGN-CD123A yielded durable complete regressions in 2 of 8 mice (p=0.0003 to untreated) whereas a higher dose of 300 mcg/kg gave complete tumor regressions in all mice (p < 0.0001 to untreated group). SGN-CD123A was also effective in a MDR-positive model of AML. A single dose of 100 mcg/kg SGN-CD123A significantly decreased tumor growth (p=0.003 to controls) whereas a single dose of 300 mcg/kg yielded durable complete regressions compared to the control groups in the KG-1 subcutaneous model of MDR-positive AML (p =0.008). Early evidence of the antitumor activity of SGN-CD123A was found in tumors harvested from THP-1 mice. Within 48h of dosing with SGN-CD123A, tumor cells showed elevated levels of the DNA damage marker γH2AX and changes in nuclear morphology. These data demonstrate that SGN-CD123A exhibits significant antitumor activity against a broad panel of primary AML samples and in preclinical models of MDR-positive AML that are characteristically resistant to chemotherapy. CD123-directed delivery of PBD may represent a promising new approach for the treatment of AML. Disclosures Sutherland: Seattle Genetics, Inc.: Employment. Yu:Seattle Genetics, Inc: Employment, Equity Ownership. Walter:Seattle Genetics, Inc: Consultancy, Research Funding. Westendorf:Seattle Genetics, Inc: Employment. Valliere-Douglass:Seattle Genetics, Inc: Employment. Pan:Seattle Genetics, Inc: Employment. Sussman:Seattle Genetics, Inc: Employment. Anderson:Seattle Genetics, Inc: Employment. Zeng:Seattle Genetics, Inc: Employment. Stone:Seattle Genetics, Inc: Employment. Klussman:Seattle Genetics, Inc: Employment. Ulrich:Seattle Genetics, Inc: Employment. Jonas:Seattle Genetics, Inc: Employment. Senter:Seattle Genetics, Inc: Employment. Drachman:Seattle Genetics, Inc: Employment. Benjamin:Seattle Genetics, Inc: Employment." @default.
• W2552830230 created "2016-11-30" @default.
• W2552830230 creator A5007674532 @default.
• W2552830230 creator A5008776383 @default.
• W2552830230 creator A5013626352 @default.
• W2552830230 creator A5017578703 @default.
• W2552830230 creator A5019036090 @default.
• W2552830230 creator A5025418128 @default.
• W2552830230 creator A5028174361 @default.
• W2552830230 creator A5039115341 @default.
• W2552830230 creator A5039496067 @default.
• W2552830230 creator A5046639473 @default.
• W2552830230 creator A5053277203 @default.
• W2552830230 creator A5063558583 @default.
• W2552830230 creator A5065128818 @default.
• W2552830230 creator A5069264475 @default.
• W2552830230 creator A5089318759 @default.
• W2552830230 creator A5090584176 @default.
• W2552830230 date "2015-12-03" @default.
• W2552830230 modified "2023-09-30" @default.
• W2552830230 title "SGN-CD123A, a Pyrrolobenzodiazepine Dimer Linked Anti-CD123 Antibody Drug Conjugate, Demonstrates Effective Anti-Leukemic Activity in Multiple Preclinical Models of AML" @default.
• W2552830230 doi "https://doi.org/10.1182/blood.v126.23.330.330" @default.
• W2552830230 hasPublicationYear "2015" @default.
• W2552830230 type Work @default.
• W2552830230 sameAs 2552830230 @default.
• W2552830230 citedByCount "16" @default.
• W2552830230 countsByYear W25528302302016 @default.
• W2552830230 countsByYear W25528302302017 @default.
• W2552830230 countsByYear W25528302302018 @default.
• W2552830230 countsByYear W25528302302019 @default.
• W2552830230 countsByYear W25528302302020 @default.
• W2552830230 countsByYear W25528302302023 @default.
• W2552830230 crossrefType "journal-article" @default.
• W2552830230 hasAuthorship W2552830230A5007674532 @default.
• W2552830230 hasAuthorship W2552830230A5008776383 @default.
• W2552830230 hasAuthorship W2552830230A5013626352 @default.
• W2552830230 hasAuthorship W2552830230A5017578703 @default.
• W2552830230 hasAuthorship W2552830230A5019036090 @default.
• W2552830230 hasAuthorship W2552830230A5025418128 @default.
• W2552830230 hasAuthorship W2552830230A5028174361 @default.
• W2552830230 hasAuthorship W2552830230A5039115341 @default.
• W2552830230 hasAuthorship W2552830230A5039496067 @default.
• W2552830230 hasAuthorship W2552830230A5046639473 @default.
• W2552830230 hasAuthorship W2552830230A5053277203 @default.
• W2552830230 hasAuthorship W2552830230A5063558583 @default.
• W2552830230 hasAuthorship W2552830230A5065128818 @default.
• W2552830230 hasAuthorship W2552830230A5069264475 @default.
• W2552830230 hasAuthorship W2552830230A5089318759 @default.
• W2552830230 hasAuthorship W2552830230A5090584176 @default.
• W2552830230 hasConcept C153911025 @default.
• W2552830230 hasConcept C159654299 @default.
• W2552830230 hasConcept C185592680 @default.
• W2552830230 hasConcept C203014093 @default.
• W2552830230 hasConcept C2777325958 @default.
• W2552830230 hasConcept C2778556491 @default.
• W2552830230 hasConcept C2778729363 @default.
• W2552830230 hasConcept C502942594 @default.
• W2552830230 hasConcept C542903549 @default.
• W2552830230 hasConcept C83396363 @default.
• W2552830230 hasConcept C86803240 @default.
• W2552830230 hasConceptScore W2552830230C153911025 @default.
• W2552830230 hasConceptScore W2552830230C159654299 @default.
• W2552830230 hasConceptScore W2552830230C185592680 @default.
• W2552830230 hasConceptScore W2552830230C203014093 @default.
• W2552830230 hasConceptScore W2552830230C2777325958 @default.
• W2552830230 hasConceptScore W2552830230C2778556491 @default.
• W2552830230 hasConceptScore W2552830230C2778729363 @default.
• W2552830230 hasConceptScore W2552830230C502942594 @default.
• W2552830230 hasConceptScore W2552830230C542903549 @default.
• W2552830230 hasConceptScore W2552830230C83396363 @default.
• W2552830230 hasConceptScore W2552830230C86803240 @default.
• W2552830230 hasIssue "23" @default.
• W2552830230 hasLocation W25528302301 @default.
• W2552830230 hasOpenAccess W2552830230 @default.
• W2552830230 hasPrimaryLocation W25528302301 @default.
• W2552830230 hasRelatedWork W1271574226 @default.
• W2552830230 hasRelatedWork W154275580 @default.
• W2552830230 hasRelatedWork W1591820460 @default.
• W2552830230 hasRelatedWork W2007433984 @default.
• W2552830230 hasRelatedWork W2529990992 @default.
• W2552830230 hasRelatedWork W3025100125 @default.
• W2552830230 hasRelatedWork W3130631450 @default.
• W2552830230 hasRelatedWork W3160362032 @default.
• W2552830230 hasRelatedWork W4214530013 @default.
• W2552830230 hasRelatedWork W4361938312 @default.
• W2552830230 hasVolume "126" @default.
• W2552830230 isParatext "false" @default.
• W2552830230 isRetracted "false" @default.
• W2552830230 magId "2552830230" @default.
• W2552830230 workType "article" @default.